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The MTX-resistant Leishmania mqjor promastigote 
cell line D7BR1000 displays  extrachromosomal  ampli- 
fied  R-region DNA, which contains the gene for dihydro- 
folate reductase-thymidylate synthase (DHFR-TS) 
(Garvey, E. P., and Santi, D. V. (1986) Science 233, 535- 
540). Now  we report  that these methotrexate (-)-re- 
sistant cells  also  possessed a structurally altered DHFR- 
TS. We have performed the cloning, expression, and 
characterization of the altered DHFR-TS gene.  The DNA 
sequence of the altered DHFR-TS  gene revealed a single 
base  change in position 158  which resulted in  the sub- 
stitution of a methionine in position 53  of  DHFR for an 
arginine. Steady-state measurements of the purified re- 
combinant  enzyme indicated that  the mutation did not 
cause significant modifications in the K,,, for DHFR or 
TS substrates but lowered the keet by  4-fold. Of greater 
interest,  there was a modification in the effect  on MTX 
inhibition of  DHFR. The initial inhibition complex a p  
peared to have  been  unaffected by the alteration, but 
the subsequent slow-binding step of inhibition in  the 
wild-type  enzyme is absent in  the  altered enzyme.  Con- 
sequently, the overall Ki for MTX was  30-fold greater for 
the mutant than for the wild-type  enzyme.  Transfection 
of L.  mqjor with the mutant DHFR-TS  gene  gives para- 
sites that  are capable of growing in medium containing 
10 m~ methotrexate, showing that  the altered DHFR 
gene  is in itself capable of conferring MTX resistance in 
Leishmania. 
Dihydrofolate reductase (DHFR)’ (EC 1.5.1.3) and thymi- 
dylate  synthase  (TS)  (EC 2.1.1.45) act  sequentially  in  the novo 
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The abbreviations used are: DHFR, dihydrofolate reductase; TS, 
thymidylate synthase; WT rLMDT, wild-type recombinant L .  major 
dihydrofolate  reductase-thymidylate  synthase; M53R rLMDT, Met-53 
to Arg mutant recombinant L .  major dihydrofolate reductase-thymi- 
dylate synthase; MTX, methotrexate (4-amino-4-deoxy-l0-methylfolic 
acid); pEl,  expression  plasmid  for WT rLMDT  pD7BE1-20,  expression 
synthesis of pyrimidines. In  parasitic protozoa, both DHFR and 
TS  exist  as a  bifunctional protein  ranging in size from 110 to  
140  kDa, with  subunit sizes of 55-70 kDa (1-3). The impor- 
tance of DHFR to  the biochemistry of the cell and  in  the  treat- 
ment of a variety of diseases  has  made  this enzyme the focus of 
numerous studies on its structure and function. In recent 
years,  the  crystal  structures of DHFR  from several prokaryotic 
and eukaryotic organisms have been determined (4-8). The 
large data base of structural information on DHFR coupled 
with  the  technique of site-directed mutagenesis  has allowed 
researchers to  investigate how the  structure of the enzyme is 
related  to  its function and  inhibition by anti-folates. In  the case 
of Leishmania  major or any  other protozoal parasite,  the crys- 
tal structure of DHFR-TS is  yet  to be determined, so an under- 
standing of the structure-function relationships in L. major 
DHFR can only be  achieved through  the  analysis of mutants 
with  altered  catalytic  and  inhibition  properties  and homology 
comparisons with other DHFRs. Such  mutants may  be  isolated 
from MTX-resistant L. major cells or may be engineered  via 
site-directed mutagenesis. 
Methotrexate (MTX) is  an  extremely  potent DHFR inhibitor 
which is often  used as  an  antiproliferative  agent.  The  binding 
of  MTX to DHFR is  characteristic of a class of inhibitors  that 
form an  initial complex which isomerizes slowly to a tighter 
complex and  are  referred to as “slow, tight-binding“ inhibitors 
(9-11). 
Considerable  effort has been  dedicated to the  understanding 
of the biochemical basis for the selectivity of  MTX and for the 
development of cellular  resistance  to  the  drug (12). It  has  been 
well established that several  individual or concurrent  mecha- 
nisms  can be responsible for resistance: amplification of the 
DHFR  gene, alteration  in  the  transport f the  drug  into  the cell, 
and expression of an  altered DHFR  protein (for reviews, see 
Refs. 13 and 14). Such  studies  have  engendered  insight  into  the 
relationship between DHFR structure and catalytic function 
and provided tools for molecular genetic studies.  In  the  par- 
ticular case of Leishmania,  resistance  to  methotrexate  can be 
attained by amplification of the gene  for DHFR-TS contained in 
an extrachromosomal  DNAcalled R-region DNA  (151, reduction 
in the permeability of cells to  the  drug  (16, 17), or by amplifi- 
cation of the chromosomal H region as extrachromosomal 
circles (17-21). 
We have explored further  the  question of  MTX resistance  in 
Leishmania and  report  here  that  the previously characterized 
plasmids  for  M53R  rLMDT;  H,folate,  dihydrofolate;  CH,-H,folate, 
methylene tetrahydrofolate; FdUMP, 5-fluoro-2’-deoxyuridine mono- 
phosphate;  PAGE,  polyacrylamide  gel  electrophoresis;  PCR,  polymerase 
chainreaction;TES, 2-[[2-hydroxy-l,l-bis(hydroxymethyl)ethyllaminol- 
ethanesulfonic  acid. 
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resistant cell line D7BR10002 contains  an  altered DHFR-TS. 
This  finding  represents  the  first description of  MTX resistance 
in Leishmania mediated by a mutation  in  the  target enzyme. 
We describe the cloning, sequencing, and expression of the 
DHFR-TS gene from this cell line  and  have identified the  mu- 
tation Met-53 to Arg as being  responsible for MTX resistance. 
An expression system for the  altered protein has been devel- 
oped and  studies on some structural  and  kinetic properties of 
the  protein  have been performed and compared with those of 
the wild-type recombinant enzyme. Experiments  are also  pre- 
sented showing that  transfection of L. ma jo r  with  the  mutant 
gene confers high levels of methotrexate  resistance  to cells. 
EXPERIMENTAL. PROCEDURES 
Materials-Restriction  endonucleases,  Taq  Polymerase,  T4 DNA li- 
gase,  and  Random  Priming  kit  were  purchased from Boehringer  Mann- 
heim Biochemicals. Methotrexate (4-amino-4-deoxy-l0-methylfolic 
acid)  was  obtained  from  the  Lederle  Parentals,  Inc. Foli  acid, H,folate, 
dUMP, FdUMP, protease inhibitors, P-NADPH, and all buffers were 
from  Sigma.  Dihydrofolate  was  prepared from folic acid by the  method 
of Blakley  (22). DNA sequencing  was  carried  out  using  the  Sequenase 
Version 2.0 from U. S. Biochemical Corp.  Reagents  and  protein  stan- 
dards  for SDS-PAGE and  IEF  were from Bio-Rad and  Serva Feinbio- 
chemical. [6-3HlFdUMP (23 Ci/mmol) and Hybond-N membranes for 
Southern  blotting  were  from  Amersham  Corp. [3',5',7-3HlMTX, sodium 
salt (32.7 Ci/mmol), was  purchased  from  Du  Pont-NEN"  Research  Prod- 
ucts. MTX-Sepharose was  prepared by coupling MTX to  aminohexyl- 
Sepharose CL-GB according to  the  method of Bethel1 (23).  Expression 
vector pKK223-3 and  Ampholiney PAG plates  pH  5.5-8.5 for IEF were 
purchased  from  Pharmacia LKB Biotechnology Inc. 
Selection and Cloning of MTX-resistant L. major and Cell Duns- 
fection-L. major promastigotes  were  derived from a clone (D7B) iso- 
lated from strain 252, Iran (S. Meshnik). Organisms were grown at 
26 "C in M199 medium (Life Technologies Inc.)  supplemented  with 20% 
fetal calf serum, 25 m~ Hepes, pH 7.4, and, when specified, MTX. 
MTX-resistant strains  ofL. major promastigotes  were  obtained by step- 
wise  selection as described for the original  MTX-resistant L. major (15). 
Clones of the D7BR1000 line  were  prepared by agar  plating  (24)  in 
collaboration with Dr. Buddy Ullman at  the Oregon Health Sciences 
University.  For  transfection  experiments,  the  wild-type L. major 252 
and L. major WR454 (Walter Reed Army Institute of Research)  (25) 
strains were  used.  Parasites  were  transfected by electroporation  and 
selected in M199 medium containing 16 pg/ml G418 (geneticin; Life 
Technologies Inc.) as described (26). Electroporation was performed 
with an  ECM 600@ Electroporation System from BTX Inc. a t  1300 
microfarads, 2,250 V/cm. Transfected  cells  were  selected for growth in 
480  pg/ml G418 and  tested for resistance  to  methotrexate.  The EC,, is 
the  concentration of  MTX (in p ~ )  which  decreases cell density by  50% 
(17).  The  presence of the  plasmid DNA as a  circular  extrachromosomal 
element  in  the  transfected cell line  was  determined by Southern  anal- 
ysis of chromosome gels. 
DNA Manipulation Procedures-Total L. major DNA was  prepared 
as described  (15). Oligonucleotide synthesis  was  performed at the  UCSF 
Biomolecular Resource Center. PCR was  performed  in  a  Perkin-Elmer 
thermocycler using Taq polymerase. Amplification was performed in 
reactions  containing  0.5  pg of genomic DNA, 25 pmol of each  primer, 
100 p~ of each dNTP, 100 m~ Tris-HC1, pH  8.4,  60 m~ MgCl,, 500 m~ 
KCl, 200 pg/ml gelatin, and 5 units of enzyme. PCR products were 
separated by electrophoresis  and  Southern blot hybridization  using the 
DHFR-TS L. major gene as  probe confirmed the  identity of the correct 
band. Bands were excised, electroeluted, and cloned in M13 mp18. 
DHFR  sequences  were  determined  using  the dideoxy chain  termination 
technique  (27);  a  series of complementary 17- and  19-mer oligonucle- 
otides derived from the DHFR and TS coding regions were used as 
primers for sequencing  single  stranded  template. 
Parasites were  embedded in  agarose blocks for pulsed  field  gradient 
electrophoresis as described (28). Chromosomes from L. major were 
fractionated  in a contour-clamped homogeneous electric field apparatus 
by pulsed-field gradient  electrophoresis  (29).  Running  conditions  were: 
Resistant cell lines  are  designated  as  R followed by the micromolar 
concentration of drug to which  they  were  resistant, e.g. RlOOO refers  to 
cells that  were  resistant  to  1000 p~ MTX. In addition,  the clone name 
of D7B is  used  as a prefix  to  differentiate  between  the  resistant  cells 
described  here  and  the  original  MTX-resistant  cells  (15). 
1-s pulses for 30  min followed by a 36-h run with  75-s  pulses a t  8.5 V/cm 
and  a  temperature of 12-15 "C (30). Chromosomes were then trans- 
ferred to Hybond-pM membranes and hybridized with a L. major 
DHFR-TS probe as described in standard protocols. The expression 
plasmids  (pD7BE1  to pD7BE20) were  constructed by cloning the EcoRI- 
Hind111 restriction  fragment from different  M13  mpl8-DHFR-TS clones 
into the expression vector pKK223-3 (Pharmacia). Escherichia coli 
x2913  (Thy-)  and PA414 (Thy-,DHFR-) (31) cells transformed  with  the 
expression plasmids were grown in LB medium  containing  50 pg/ml 
ampicillin. All general DNA manipulations  not  mentioned  were as de- 
scribed  (32). 
Protein Analysis-Leishmania crude  extracts,  either for determina- 
tion of DHFR-TS  levels  or for characterization of the bifunctional pro- 
tein,  were  prepared  as  reported  (33).  Electrophoretic  procedures  were 
performed as previously  described  (34). Two-dimensional electrophore- 
sis  was  performed by Protein  Database  Inc., modifying the  procedure of 
OFarrell  (35).  Recombinant M53R and wild-type L. major DHFR-TS 
were isolated and purified as  previously described (33, 36). For TS 
quantifications,  covalent  TS.[3HlFdUMPCH,-H,  folate complexes were 
formed as  indicated  (37).  Nondenaturing  isoelectric focusing was  per- 
formed in  the  precasting  polyacrylamide  gels above indicated.  The pH 
gradient was determined by electrophoresis of colored protein stan- 
dards  with  known  isoelectric  points  (PI = 4.7-10.6 and 3.5-10.5). Elec- 
trophoresis was performed in a LKB 2117 Multiphor electrophoresis 
system at 8 watts for 5000 V-h. Gels  were  previously focused a t  6  watts 
for 600 V-h. 25  pg of purified  protein in a  final volume of 5 pl  were 
charged a t  2.5 cm from negative  electrode  to avoid precipitation.  After 
electrophoresis, gels were  subsequently fixed and  stained as described 
(33). 
The rate of I3H1MTX dissociation from the MTX.NADPH.enzyme 
complex was  determined by: 1) incubating  6  pg  (54.5 pmol) of M53R 
rLMDT or 3.6 pg  (32.7 pmol) of WT rLMDT with  100 PM NADPH and 
0.1 p~ C3H1MTX in 0.6 ml of 50 m~ TES,  pH  7.4,2 mM dithiothreitol,  and 
1 m~ EDTA, at 25 "C, for 45  min;  2)  initiating  dissociation by addition 
of 50 p~ cold  MTX, and  3)  separating  the  macromolecular-bound from 
free c3H]MTX by filtering 100-1.11 aliquots of the reaction mixture on 
small  columns of Sephadex G-15 by a previously described method  (2); 
the chromatographic  separation  was  performed at  4 "C. To quantitate 
the complex formed, it was assumed that DHFR-TS binds 1 mol of 
MWmol  of dimer (33). 
Steady-state kinetic data were obtained with a Hewlett-Packard 
8452A Diode Array  Spectrophotometer  interfaced  with  a Compaq PC. 
Data  were  translated  and  the  computer  program  KaleidaGraphTM 2.0 
was  used  to  analyze data. DHFR and  TS specific activities  were moni- 
tored at 25 "C at  340  nm.  The  DHFR  and  TS  standard  assays  were  as 
described  (15). To determine  the  character  and  extent of MTX inhibi- 
tion, 0-1000 n~ MTX was  included, the reaction  was  then  initiated  with 
4.2 IIM M53R rLMDT. The K, for wild-type  enzyme  was  determined by 
including 0-30 nM MTX, and  initiating  the  reaction  with  0.8 n~ wild- 
type  enzyme. H,folate concentration  was  kept fixed at 0.1 p ~ .  K,,,values 
for NADPH, H,folate, CH,-H,folate, and  dUMP  were  obtained by vary- 
ing  the  substrate  at  subsaturating  concentrations  while  keeping  the 
other  at  constant  saturating  concentrations.  Nonlinear  regression  anal- 
ysis  using  Enzkinetic  was  used  to  determine  both kc,, and K ,  values. 
Concentrations  were  determined  spectrophotometrically  using  molar 
extinction coefficients of 28,000 cm" at  282 nm for H,folate (22,38), 
6,220 cm" at 340 nm for NADPH (39)  and  22,100 M" cm" at 302 nm, 
pH  13, for MTX (38).  The  molar  extinction coefficients for H,folate and 
CH,-H,folate utilization by DHFR and TS were 12,300 and 6,400 
M - ~  cm" at  340 nm,  respectively  (40).  Protein  concentrations  were ob- 
tained  either by Bradford  determinations  or for purified  enzyme,  using 
a molar  extinction coefficient for DHFR-TS of 87,600 cm" a t  280 nm. 
All other  protein  techniques  not  mentioned were as described (33). 
RESULTS AND DISCUSSION 
DHFR-TS i n  D7B Crude  Extracts-It has been reported that 
the properties of DHFR-TS from the L. major  cell lines RlOOO 
(resistant  to MTX) or CB50 (resistant  to CB3717) (41) were 
indistinguishable from those of the enzyme  isolated from wild- 
type cells and  that  the major mechanism of drug  resistance  in 
these cells was gene amplification (18, 41). When compared 
with levels of DHFR-TS in wild-type cells, Le ishmania  D7B 
cells resistant to 10, 50, 100, and 1000 PM MTX showed in- 
creased levels of the bifunctional  protein (Table I). However, 
the levels of TS, and especially DHFR, did  not  directly  correlate 
with the concentration of drug to which the cells were resistant 
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TADLE I 
DHFR and TS levels in crude  extracts  from D7B cells resistant  to 
MTX and  from  wild-type cells 
Each value is  an average from at  least four different preparations of 
crude extract from the given cell line; each preparation taken from cells 
at  least  10 generations apart. Each determination consists of assaying 
a crude extract for DHFR activity, TS binding, and protein; and each 
assay is done at  least twice, with  the average taken. 
Cell type DHFR TS Ratio D H F W S  
unitslmg pmol I mg unifslpmol 
Wild-type 8 t 2   4 + 2  
R10 
1.5 
40 t 20 30 + 10 
R50 
1.3 
35 + 9 90 t 20 0.4 
RlOO 10 t 3 50 t 30 
R l O O O  
0.2 
15 t 5 70 2 20 0.2 
and the amount of DHFR-TS overproduction. The L. major 
D7BR1000 line overproduced the bifunctional  protein 
DHFR-TS by amplification of a region of  DNA called R-region 
DNA that  contains  the gene for DHFR-TS (28). D7B R-region 
DNA was significantly larger  than  the  other DNAs (42 versus 
30 kilobases) and occurred in a different pattern from that 
observed in  previous resistant cell lines. We have  determined 
by contour-clamped homogeneous electric field electrophoresis 
and  Southern hybridization that  the D7B cells resistant  to  10, 
100, and 1000 p~ MTX possessed, respectively, 2 5 ,  1 5 ,  and 
30-fold increases of the R-region DNA when compared to  the 
wild-type copy number  (results not  shown). Other MTX-resist- 
ant cells (15)  and  the cells resistant  to high levels of CB3717 
(41)  had shown a t  least  an 85-fold increase in copy number. In 
addition, when copy number  was  determined  during  the selec- 
tion of CB3717-resistant cells, the level increased proportion- 
ately  to  the concentration of drug  to which cells were resistant. 
Therefore, although DNA amplification had occurred in the 
MTX-resistant D7B cells, the  amount of amplification in cells 
resistant  to 1 mM MTX was significantly less  than  in  resistant 
cells previously described. 
The  ratio of DHFR activity to  amount of TS (unit:pmol) is a 
fairly constant  number in crude  extracts of wild-type, the origi- 
nal MTX-resistant cells, and CB3717-resistant cells (Table I). 
This  ratio  is usually  between 1.5 and 2.0, but  it  can be higher 
due  to  the lability of TS (33). When we examined D7B cells 
resistant  to 50 p~ or higher concentrations of  MTX, we found 
that  the  ratio f activity of DHFR to  amount of TS  was signifi- 
cantly lower than  the  ratio  in  either D7BR10 or wild-type cells 
(Table I). Considering these  and  the DNA results previously 
mentioned, we were  curious to  see if DHFR-TS had been  al- 
tered  during  the selection process. We analyzed the  crude ex- 
tracts from wild-type and D7BR1000 cells by two-dimensional 
electrophoresis  (Fig. 1). Initially, we located DHFR-TS on the 
two-dimensional map by immunoprecipitating DHFR-TS from 
crude  extracts of D7BR1000 cells, and  then examined wild-type 
and D7BR1000 whole crude  extracts.  Extracts from D7BR1000 
cells showed a new spot which had a slightly more basic PI 
relative  to  the wild-type DHFR-TS (Fig. U?). The  relative in- 
tensity of the new spot was  approximately 5 times  greater'than 
the  spot  that corresponded to wild-type DHFR-TS (as shown by 
densitometry). At least two other major new spots also ap- 
peared  in  the D7BR1000 map,  relative  to  the wild-type map: an 
acidic protein, with an approximate  molecular mass of 40  kDa, 
and a protein  with an approximate  molecular mass of 45 kDa 
and PI of about 6.8. These proteins might  result from the co- 
amplification of other genes during  the  drug selection process 
but  are probably irrelevant  to  drug  resistance since, as shown 
below, transfection experiments of the DHFR-TS gene into 
Leishmania demonstrate  that  the nzyme is  in itself  sufficient 
to confer resistance of cells to MTX. To summarize, when ex- 
tracts from MTX-resistant cells were  analyzed either for 
A. B. C. 
Acidic Base Acidic Base Acidic Base 
FIG. 1. Two-dimensional gel electrophoresis of wild-type (A) 
and D7BR1000 ( B )  crude extracts and immunoprecipitate of 
D7BR1000 crude extract ( C ) .  Figures show the upper right-hand 
corner of the two-dimensional maps, so that  the pH gradient runs from 
approximately 6 to 8, and the molecular mass decreases from the origin 
to approximately 25 kDa. The large arrows point to the spots which 
represent wild-type and the  mutant DHFR-TS. The spot described in 
the  text  that is present in  the D7BR1000 extract and absent  in wild- 
type extract is directly to the basic side of the wild-type DHFR-TS, at 
the  same molecular weight. The small  arrows point to the spots which 
represent other proteins that are increased in D7BR1000. 
amount of DHFR-TS or for possible structural changes in 
DHFR-TS, data  was consistent  with the existence of an  altered 
bifunctional protein. 
Cloning and Sequencing of the MZ-resistant DHFR-TS 
Gene-Several clones of L. major D7BR1000 cells were ob- 
tained by a previously described procedure (24)  and grown in 
media with 1 mM MTX. DHFR and  TS specific activities were 
measured  in  crude  extracts of these cells and compared with 
the corresponding values from nonresistant  and classical resist- 
ant L. major (R1000-11) cells (18) (Table 11). All of the clones 
examined presented a decreased D H F W S  ratio compared to 
wild-type cells suggesting that  an  altered DHFR-TS was  pre- 
sent  in all cases. One clone (C6)  presented  the most  different 
value of DHFWTS (0.56) compared to  that from wild-type cells 
(4.4) so we selected this clone for further  studies  assuming  that 
the probability of isolating an altered DHFR sequence was 
higher  in  this case. 
Total DNA from the 1 mM MTX-resistant L. major 
D7BR1000-C6 was isolated and used as  template  in  the po- 
lymerase  chain reaction to amplify DHFR-TS sequences and 
facilitate  isolation of the DHFR-TS gene. Primers complemen- 
tary  to  the L. major DHFR-TS gene  were designed introducing 
an EcoRI and a HindIII  site at  the 5' and 3' ends, respectively, 
for convenient cloning of the PCR products in M13. The correct 
identity of the 1583-base pair PCR product was verified by 
hybridization  with the DHFR-TS gene from wild-type L. major. 
The PCR product  was digested with EcoRI and  HindIII,  then 
directionally cloned between EcoRI and  HindIII  sites in M13 
mp18 and  transformed in E. coli XL1-Blue cells; 20 positive 
clones were randomly selected for further study. Single and 
double strand DHFR-TS M13 DNA from each of these clones 
was isolated, checked by restriction analysis,  and  the  entire 
DHFR domain insert sequences of the 20 M13 clones were 
determined. The sequences in  19 clones were identical to the L. 
major DHFR-TS DNA sequence  reported by Beverley et al. (421, 
except a t  position 2 of codon 53 (ATG to AGG) which would 
cause a methionine to arginine substitution. In one of the 
clones a second mutation  (T  instead of C a t  nucleotide position 
607) giving rise  to a Thr-202 to Met change in  the DHFR  do- 
main was also detected. We do not know if this change is  due to 
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TABLE I1 
resistant  to  MTX  and  wild-type  cells 
DHFR  and TS levels in crude  extracts  from  Rl000-11,  D7B clones 
strain 252 




























6 1 4.4 
28 13 2.1 
19 22 0.8 
20  25 0.8 
14 18 0.8 
16  21  0.8 
25  25  1.0 
9  16 0.6 
15 12 1.2 
For this work D7BR1000 was cloned again  and clone 6 used for 
Values correspond  to the  average of two determinations. 
POJl corresponds  to  a  wild-type clone of L.  major 252 Iran. 
R1000-11 corresponds  to  a L.  major 252 strain  resistant  to 1 mM 
MTX proceeding from an heterogeneous  population of cells  and  cultured 
in presence of inhibitor for 11 months. 
D7BR1000 corresponds  to  a L.  major 252 strain  resistant  to 1 mM 
MTX but proceeding from a clone of parasites  called D7B. 
a PCR artifact or if it  has  any significance in  the kinetic prop- 
erties of the enzyme; preliminary studies of DHFR activity in 
crude  extracts show no significant differences between  single 
and double mutants  (data not  shown). The  TS domain from the 
PCR clone 5 was also sequenced. Apart from the Met-53 to Arg 
substitution,  there were no differences with regard to the L. 
major DHFR-TS cDNA sequence previously described (42). The 
fact  that all 20 clones sequenced showed the M53R mutation 
strongly suggests  that  the D7BR1000 clone origin of these PCR 
clones contained a predominance of the  altered gene  with little 
or no contamination by wild-type. 
Expression and Purification of Recombinant DHFR-TS-The 
expression  plasmid containing  the DHFR-TS gene was  trans- 
formed into lac IQ E. coli XL1-Blue hosts  and  the  authenticity of 
the plasmid constructs was again verified by restriction  anal- 
ysis. All plasmids complemented growth ofE. coli cells deficient 
in  TS  (~2913) or DHFR and TS(PA414), showing that  catalyti- 
cally active TS  and DHFR were  expressed. We chose the plas- 
mid pD7BE5 (derived from the M13 clone 5 whose thymidylate 
synthase sequence had been fully verified) for further studies. 
The M53R rLMDT and WT rLMDT in  extracts from pD7BE5 
and  pEl  transformed E. coli $2913, respectively, were purified 
to  apparent homogeneity by MTX-Sepharose affinity  chroma- 
tography as previously described (33). In both cases the  puri- 
fied bifunctional protein exhibited a single band with M, 
55,000 by SDS-PAGE (Fig. 2). The purified, recombinant bi- 
functional  protein M53R rLMDT expressed in  transformed E. 
coli exhibited TS  and DHFR average specific activities of 2,000 
TS units/mg  and 3,500 DHFR units/mg. This  is  in  contrast  to 
the final specific activities of approximately 2,000 TS  units/mg 
and 20,000 DHFR units/mg observed when recombinant WT 
rLMDT is purified. These specific activities of wild-type en- 
zyme from pEl  were similar  to  those  determined  with  the  best 
preparation from Leishmania cells (33). 
Multiple experimental evidence supports  the existence of a 
more basic mutant protein. First,  the isoelectric point of  M53R 
and WT proteins  was  determined by nondenaturing horizontal 
isoelectrofocusing: native M53R rLMDT and WT rLMDT PI 
values were 6.6 0.2 and 6.4 2 0.2, respectively. Second, non- 
denaturing polyacrylamide gel electrophoresis  was performed 
on the purified mutant protein.  A band with  a  slightly slower 
migration than wild-type was obtained indicating a shift to- 
wards a more positively charged  protein (results  not shown). 
Kinetic Characterization of Purified M53R  rLMDT-The ki- 
netic  parameters of M53R rLMDT were measured (Table 111). 
further  studies. 
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FIG.  2. Purification of recombinant M53R and WT D m - T S  
expressed in E. coli (pD7BE5 and  pEl, respectively), 12,570  SDS- 
PAGE stained with Coomassie R-250. Arrow indicates DHFR-TS. 
Lane A, pEl-transformed E. coli, crude  soluble  extract; lane B ,  pEl- 
transformed E. coli MTX-Sepharose flow through; lane C, pEl-trans- 
formed E. coli MTX-Sepharose-purified DHFR-TS; lane D, pD7BE5- 
E. coli MTX-Sepharose flow through; lane F, pD7BE5-transformed E. 
transformed E. coli, crude  soluble  extract; lane E,  pD7BE5-transformed 
coli MTX-Sepharose-purified DHFR-TS. 
TABLE I11 
Michaelis  constants  and  steady-state  rates  for  the reactions catalysed 
by wild-type  and  M53R  rLMDT 
Activity Enzyme 
K ,  (PM) 
k,,, (s-') 
NADPH H,folate 
DHFR Wild-type 0.9 2 0.1 1.3 f 0.3  29 .c 7 
M53R 1.2 f 0.2 1.62 0.3 7.6 2 0.8 
dUMP (6R,S)1,-CH,-H,folate 
TS Wild-type 7.0 2 0.6 79 f 5 
M53R 
5.8 f 0.9 
6.5 -r 0.9  96 2 6 5.5 f 0.7 
The K, and  the kc,, values of TS  substrates were essentially the 
same for wild-type and  mutant DHFR-TS. There were no  dif- 
ferences  between wild-type and  mutant enzyme in  the K,,, val- 
ues for NADPH and dihydrofolate, but kc,, for M53R  rLMDT 
from D7BR1000 cells was lower than  the wild-type enzyme by 
a factor of 4. This lower turnover number of DHFR partly 
explains the low ratios of DHFR to TS  that were observed in 
crude  extracts. Values of the  steady-state kinetic constants ob- 
tained for wild-type enzyme in this  study were  approximately 
the  same  than those  reported previously (33). 
We analyzed the interaction of  MTX with DHFR by two dif- 
ferent approaches: measuring  the  rate of dissociation of 
['HIMTX from the MTX.NADPH.enzyme complex, and analyz- 
ing  the progress  curves of DHFR activity in  the presence and 
absence of  MTX. When we used pure WT rLMDT and measured 
the  rate of MTX dissociation from the  ternary complex, the 
results were similar to those previously measured (33, 36); 
MTX dissociated with k = 0.046 min" (Fig. 3A). When we used 
purified M53R  rLMDT,  we obtained quite different results (Fig. 
3B). The radioactivity detected at  the  initial  time point was 
only 5% of what was expected; and  during  the first minute after 
the cold  MTX was  added,  a very rapid loss in radioactivity was 
observed. We interpreted  the  rapid rop of radioactivity  during 
he  first  minute as representing  the  rate of  MTX dissociation 
from the structurally altered DHFR-TS in the presence of 
NADPH which was too fast to measure by this assay. Thus, the 
alteration in DHFR-TS appeared  to  cause DHFR to bind less 
tightly to MTX. 
MTX inhibition of wild-type Leishmania DHFR has been 
previously reported to  have  an  apparent Ki = 0.13 t 0.04 nM 
when analyzed by the method of Cha (33). We further examined 
the steady-state inhibition patterns from WT rLMDT and 
M53R rLMDT by progress  curve analysis (11). When the DHFR 
reaction was initiated with wild-type enzyme and the MTX 
concentration was varied from 0 to 30 nM, a time-dependent 
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FIG. 3. Rates of MTX dissociation from the MTX.NADPH- 
enzyme  complex. A, shows the  rate observed when wild-type rLMDT 
was  used. B,  displays the  results  when M53R rLMDT purified  enzyme 
was  used.  The  assay is described  under  "Experimental  Procedures." 
inhibitor  concentration (Fig. 4A). The  kinetics were character- 
istic of MTX-DHFR interactions  where  the  initial  step involves 
rapid  formation of a weak complex, followed by a slow conver- 
sion to  the  tight-binding complex. We obtained a value for the 
rate  constant of this slow-binding process by assuming it was 
analogous to  enzyme  inactivation by a slow, tight-binding in- 
hibitor (11). First,  the progress curves  were  analyzed by assum- 
ing that the  rates of inactivation reflected  a  pseudo-first order 
process; we computer-fitted the  data  to  Equation 1: 
[NADP] = U& - (u,, - ~ ~ ) ( l + - ' ~ ) / k ~ ~  (Eq. 1) 
where ui and uf are  the  initial  and  final DHFR steady-state 
rates,  and kobs is the pseudo-first order  rate  constant (43). The 
reciprocal of the observed pseudo-first order rate constants 
were plotted versus the reciprocal of the MTX concentration, 
employing Equation 2: 
where K, is the  equilibrium  constant for the  initial  inhibition 
complex, and kslow bind is  the  rate  constant for the slow-binding 
process of inhibition. The kslow bind for the wild-type  enzyme was 
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FIG. 4. Character and extent of DHFR inhibition by "X. A, 
progress curves for the slow development of inhibition of wild-type 
DHFR by MTX, reactions  were  started by addition of enzyme  (1.6 mi). 
e ,  30 mi. B ,  reactions  rates for the  inhibition of M53R rLMDT by  MTX. 
Concentrations of MTX are  as follows: a ,  0; b, 5 n M ;  c, 10 mi; d ,  15 nM; 
Reactions  were  started by addition of enzyme (8.2 mi). Concentrations 
of  MTX were as follows: a ,  0; b, 100 mi; c, 200 mi; d ,  500 mi; e, 700 nM; 
fi 1000 n M .  
TABLE IV 
Summary of interaction between MTX and  wild-type 
and M53R DHFR 
The K, for the wild-type  DHFR  was  determined by multiplying  the K, 
for the  initial  inhibitory complex (36.6 m i )  by the  ratio of the  rates for 
dissociation  and  association of the slow-binding complex. The K, for the 
M53R enzyme was determined by assuming competitive inhibition 
kinetics. 
Process Wild-type M53R 
Rate of  13H]MTX dissociation 0.046 min" Not detectable 
Rate of the slow-binding 9.4 min" Not detectable 
K, (overall) 
from the  ternary complex 
step of inhibition 
0.18 mi 5.8 n~ 
similar  to  those  reported for the  interaction of MTX with DHFR 
isolated from Streptococcus faecium A, 5.1 min" and 23 nM, 
respectively (43). When recombinant mutant DHFR-TS from 
D7BR1000-C6 cells was  used  in  these  studies, both the  appear- 
ance of the "progress  curves" and  the  extent of inhibition at any 
given concentration of MTX were greatly changed (Fig. 4B). 
A Mutant  DHFR-TS from 
TABLE V 
MTX resistance in transfected L. major lines 
Methotrexate 
Cell line Transfected plasmid 
EC," Resistanceb 
PM -fold 
L. major wR454  N ne  0.5 
pX63NEO 
oX63NEO DT 80 
0.8 
= 100 
bX63NEO M53R DT >lo4 >10000 
pX63NEO 
pX63NEO DT 103 250 
pX63NEO  M53R DT >lo4 >2500 
L. major 252  None 2.5 
4 
a The methotrexate  EC,, is the concentration (p") which reduces the 
cell  number  bv 50%. measured when drug-free  control  culture was in 
transfected cells) and experimental  cell h e s .  
Although the  steady-state  rate was inhibited at  high concen- 
trations of MTX (above 50 n~), this  rate  was  linear  and  there 
was no time-dependent decrease in the reaction rate with 
M53R DHFR-TS. The K, for MTX inhibition of the  mutant was 
5.8 n~ which is some 30-fold higher  than  the inhibition con- 
stant for the wild-type enzyme (Table IV). 
Dansfection of Wild-type L. major with the MTX-resistant 
DHFR-TS Gene-To ensure  that  the M53R mutation was in 
itself  capable of conferring MTX-resistance in  Leishmania, we 
transfected two wild-type strains of L. major with both the 
wild-type and  mutant DHFR-TS genes. It  has been previously 
demonstrated  that transfection of Leishmania promastigotes 
with  the wild-type DHFR-TS gene renders MTX-resistant 
parasites (44). The protein coding regions  were inserted  into 
the  Leishmania expression vector pX63NEO (45)  to give 
pX63NEODT and pX63NEOM53RDT and  used to transfect L. 
major 252 (the wild-type strain from which D7B cells are de- 
rived) (15) and L. major WR454 (25). Strain  wR454  transfected 
with pX63NEODT showed approximately 100-fold greater 
methotrexate  resistance  than cells transfected with the control 
pX63NEO (Table V), while cells transfected  with  the  mutant 
construct pX63NEOM53RDT showed more than 10,000-fold 
methotrexate  resistance compared to control cells. When the 
252 strain  was  tested for resistance, EC,, values for cells trans- 
fected with the mutant gene were over 2,500-fold those ob- 
tained for control cells transfected with pX63 NE0  (Table V). 
Limitations of methotrexate solubility  prevented  precise deter- 
minations of  EC,, values for highly resistant cells. 
Gene Amplification versus Structural Mutation-A question 
that  arises is whether  gene amplification or enzyme alteration 
occurred first. We suspect  that amplification of the R-region 
DNA occurred prior to  alteration of DHFR-TS. In  the  first se- 
lection step examined, D7B cells resistant to 10 PM MTX 
showed a 25-fold increase  in R-region DNA  copy number  and a 
7-fold increase in the amount of DHFR-TS with a ratio of 
DHFR to TS  the  same  as  that  in wild-type cells. Therefore, R10 
cells possessed amplified DNA and overproduced a wild-type 
enzyme. Cells resistant  to 50 p~ MTX appeared  to  represent  an 
intermediate  stage of resistance  where  the enzyme  was over- 
produced but cells displayed the  first decline in   the  DHFWS 
ratio  (a decrease from 1.5 to 0.4). Thus, of the cells we exam- 
ined, R50 cells marked  the  first cell line  that  appear  to possess 
an  altered enzyme. Cells resistant  to 1000 VM MTX represented 
the  final  stage of resistance. The copy number of the R-region 
DNA and  the  altered DHFR-TS level increased only 2-fold from 
RlOO to RlOOO cells. Therefore, to  our  best  understanding,  the 
stepwise selection  procedure produced the following responses: 
(a) amplification of the R-region DNA during  the  initial  steps; 
( b )  an  alteration of the DHFR portion of the bifunctional pro- 
MTX-resistant  Leishmania 10595 
tein at the R-region DNA level during  the  intermediate  steps; 
and (c) a final resistant stage that was characterized by a 
predominant population of mutant DHFR and amplified R- 
region DNAs. It  appears  that cells with an  altered DHFR-TS 
were favorably selected in response to  drug  pressure  instead of 
those  containing the wild-type gene. 
Structural Basis for Resistance-Although primary struc- 
tures of DHFRs  may be less  than 25% homologous, comparison 
of x-ray structures  has revealed striking conservation of three- 
dimensional structure  as well as the amino  acids in  the active 
site  (4, 5,  8). From homology comparisons,  Met-53 in L. major 
DHFR-TS is equivalent to Leu-28 in E. coli and Phe-31 in 
human  and mouse  DHFRs (4-81, which have been implicated in 
binding of anti-folates.  For  example,  Phe-31 to Trp or Arg in 
murine DHFR (46,  47), or Phe-31 to  Ser  in  human DHFR (48, 
49) have been reported to confer MTX resistance.  The  residues 
corresponding to Met-53 of L. major DHFR form a hydrophobic 
binding pocket for the p-aminobenzoyl moiety of  MTX, and it is 
reasonable to propose that  insertion of the positively charged 
Arg in  the M53R mutant  has a detrimental effect on this  in- 
teraction. 
Summary-We have shown that  the MTX-resistant  Leish- 
mania cell line, D7BR1000, contains an  altered DHFR-TS 
which reduces  both DHFR activity and inhibition by  MTX. This 
is the  first example of a structural modification causing  anti- 
folate resistance  in  Leishmania,  and offers a counterpart  to  the 
more commonly observed mechanism involving gene amplifica- 
tion in  these organisms. The genesis of the  resistant cell line 
seems  to  have involved initial amplification of the DHFR-TS 
gene, followed by mutation of DHFR, and  then selection for 
cells containing the MTX-resistant mutant enzyme. Cloning 
and DNA sequencing of the DHFR-TS gene  revealed a single 
base  change which resulted  in a M53R mutation.  The hypoth- 
esis  that  this single mutation could confer cell resistance to 
MTX was verified by transfection of the gene into wild-type L. 
major, and  demonstration  that  the cells were highly resistant 
to MTX. Kinetic studies of the wild-type and  mutant enzymes 
revealed the  reason for MTX resistance. As observed with sev- 
eral  other DHFRs (43,50),  the wild-type enzyme interacts with 
MTX by an  initial  rapid  interaction  to give a weak complex, 
followed  by a slow step which results  in  the very tight complex. 
In  contrast,  the  resistant DHFR showed no slow onset of inhi- 
bition, and a  binding constant for MTX which was about 30-fold 
higher  than  the wild-type enzyme. 
Given the importance of DHFR as a drug  target, a clarifica- 
tion of the molecular features  that confer drug  resistance could 
aid  the  rational design of alternative  drugs  against leishmani- 
asis. Indeed our observation implicating the side chain of 
Met-53 in the altered DHFR function may be of use in the 
structure-based design of new anti-folates as selective chemo- 
therapeutic  agents. Finally, the  structurally  altered MTX-re- 
sistant DHFR-TS may be of great  utility  in transfection  experi- 
ments. This gene could function as a new drug resistance 
marker  in  the positive selection of transfected  trypanosoma- 
tids. Experiments  are  in progress to  investigate  this possibility. 
Acknowledgment-We thank Dr. Stephen M. Beverley for generously 
providing the pX63NEO vector. 
REFERENCES 
1. Ferone, R., and Roland, S .  (1980) Proc. Natl. Acad. Sci. U. S. A. 77,5802-5806 
2. Garret, C. E., Coderre, J. A,, Meek, T. D., Garvey, E. P., Claman, D. M., 
Beverley, S. M., and  Santi, D. V. (1984) Mol. Biochem. Parasitol. 11,257-265 
3. Ivanetich, K. M., and  Santi, D. V. (1990) FASEB J. 4, 1591-1597 
4. Bolin, J. T., Filman, D. J., Matthews, D. A,, Hamlin, R. C.,  and Kraut, J. (1982) 
5. Matthews, D. A., Bolin, J. T., Burridge, J. M., Filman, D. J., Volz, K. W., 
J. Biol. Chem. 267, 13650-13662 
Kaufman, B. T., Beddell, C. R., Champness, J. N., Stammers, D. K., and 
Kraut, J. (1985) J. Biol. Chem. 260, 381-391 
6. Volz, K. W., Matthews, D. A., Alden, R. A,, Freer, S .  T., Hansch, G.,  Kaufman, 
10596 A Mutant  DHFR-TS  from 
B. T., and  Kraut, J. (1982) J. Biol. Chem. 257,252%2536 
7. Stammers, D. K., Champness, J. N., Beddell, C. R.,  Dann, J. G., Eliopoulos, E., 
8. Oefner, C., DArcy, A,,  and Winkler, F. K. (1988) Eur. J. Biochem. 174,377-385 
Geddes, A. J., Ogg, D., and  North,A. C. T. (1987) FEBS Lett. 218,178-184 
9. Cha, S. (1975)Biochem. Pharmacol. 24,2177-2185 
10. Williams, J .  W., and  Momson, J .  F. (1979) Methods Enzymol. 63,437466 
11. Momson,  J. F., and  Walsh, C. T. (1988)Adu. Enzymol. 61,201-301 
12. Schweitzer, B. I., Dicker, A. P., and  Bertino, J. R. (1990) FASEB J.  4. 2441- 
13. Harrap, K. R., and  Jackson, R. C. (1978)Antibiot. Chemother. 23,228-237 
14. Bruchovsky, N., and Goldie J. H. (1982) Drug and Hormone Resistance in 
15. Coderre, J .  C., Beverley, S. M., Schimke, R. T., and  Santi, D. V. (1983) Proc. 
16. Kaur, K., Coons, T., Emmett, K., and  Ullman, B. (1988) J. Biol. Chem. 263, 
18. Beverley, S. M., Coderre, J .  C.,  Santi, D. V., and  Schimke, R. T. (1984) Cell 38, 
17.  Ellenberger, T. E., and Beverley, S. M. (1989)J. Biol. Chem. 264,15094-15103 
19. Katakura, K., and  Chang, K. P. (1989) Mol. Biochem. Parasitol. 34, 189-192 
20. Petrillo-Peixoto, M. L., and Beverley, S. M. (1988) Mol. Cell. Biol. 8,518E-5199 
21. White, T. C., Fase-Fowler, F., van  Luenen,  H.,  Calafat, J., and  Borst, P. (1988) 
22. Blakley, R. L. (1960) Nature 188, 231-232 
J.  Biol. Chem. 263, 16977-16983 
23. Bethell, G. S., Ayers, J. S., Hancock, W. S., and  Hearn, M. T. W. (1979) J. Biol. 
24. Iovannisci, D. M., and  Ullman, B. (1983) J.  Parasitol. 69, 633436 
25. Lawrie, J. M., Jackson, P. R., Stiteler, J. M., and Hockmeyer, W. T. (1985)Am. 
26. Kapler, G. M., Coburn, C. M., and Beverley, S. M. (1990) Mol. Cell. Biol. 10, 
27. Sanger, F., Nicklen, S., and  Coulson, A.  R. (1977) Proc. Natl. Acad. Sci. U. S. A. 
2452 
Neoplasia, Vol. 1, CRC Press,  Inc., Boca Raton,  FL 




J.  Dop. Med. Hyg. 34, 257-265 
1084-1094 
28. Garvey, E. P., and  Santi, D. V. (1986) Science 233,535-540 
29. Chu, G., Vollrath,  D.,  and  Davis, R. W. (1986) Science 234, 1582-1585 
30. Galindo, I . ,  and Ramirez Ochoa, J. L. (1989) Mol. Biochem. Parasitol. 34, 
74,5463-5467 
245-252 
MTX-resistant  Leishmania 
31. Ahrweiller, P. M., and  Frieden, C. (1988) J.  Bacteriol. 170, 3301-3304 
32.  Sambrook, J.,  Fritsch, E. F., and  Maniatis, T. (1989)  in Molecular Cloning:  A 
Laboratory Manual, 2nd  Ed., Cold Spring  Harbor  Laboratorv  Press, Cold 
33. Meek, T. D., Garvey, E. P., and  Santi, D. V. (1985) Biochemistry 24,678486 
34. Garvey, E. P., and  Santi, D. V. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,7188- 
Spring  Harbor, NY 
7192 
35.  OFarrell, P. H. (1975) J. Biol. Chem. 250, 40074021 
36. Grumont, R., Sirawaraporn, W., and Santi, D. V. (1988) Biochemistry 27, 
37. Sirawaraporn, W., Sirawaraporn, R., Cowman,A. F., Yuthavong, Y., and  Santi, 
38. Stone, S. R., Montgomery, J. A,, and  Momson, J. F. (1984) Biochem. Pharma- 
. ~. 
37763784 
D. V. (1990) Biochemistry 29, 10779-10785 
col. 33. 175-179 
39.  Penner, M . ,  and  Frieden, C. (1985) J.  Biol. Chem. 260,536G5369 
40. Baccanari, D. P., Phillips, A,, Smith, S., Sinski, D., and Burchall, J. (1975) 
41. Garvey, E. P., Coderre J. C., and  Santi, D. V (1985) Mol. Biochem. Parasitol. 
42. Beverley, S. M., Ellenherger, T. E., and Cordingley, J. S. (1986) Proc. Natl. 
43. Williams, J. W., Momson, J. F., and Duggleby, R. G.  (1979) Biochemistry 18, 
45. LeBowitz, J. H., Cobum,  C.  M.,  and Beverley, S. M. (1991) Gene (Amst. 1 103, 
44. Callahan, H. L., and Beverly, S. M. (19921 J.  Biol.  Chem. 267, 24165-25168 
46. MacIvor, R. S., and  Simonsen, C. C. (1990) Nucleic Acids Res. 18, 7025-7032 
47. Thillet, J . ,  Absil, J . ,  Stone, S. R., and Pictet, R. (1988) J.  Biol. Chem. 263, 
48.  Schweitzer, B. I., Srimatkandada, S., Gritsman,  H., Sheridan, R., 
12500-12508 
Venkataraghavan, R., and  Bertino, J. R. (1989) J.  B i d .  Chem. 264, 
20786-20795 
49.  Srimatkandada, S., Schweitzer, B. I., Momson, B. A., Dube, S., and  Bertino, J .  
R. (1989) J. Biol. Chem. 264, 3524-3528 
50. Appleman, J. R.,  Prendergast, N., Delcamp, T. J., Freisheim, J. H.,  and  Blak- 
ley, R. L. (1988) J.  Biol. Chem. 263, 10304-10313 
Biochemistry 14, 5267-5273 
17, 79-91 
Acad. Sci. U. S. A. 83, 2584-2588 
2567-2573 
119-123 
